Morgan Keegan Maintains Market Perform Rating on Johnson & Johnson

According to Morgan Keegan, Johnson & Johnson

Market Perform rating is reiterated. Morgan Keegan said that Johnson & Johnson reported sales roughly in line with expectations, with EPS beating estimates due to a lower than expected tax rate. “We continue to rate JNJ shares Market Perform with a $68 price target, and note that investors who want exposure to one of the more stable companies in healthcare would do well to hold shares.” KEY POINTS Johnson & Johnson closed yesterday at $65.